BiosanaPharma

Just months after announcing that it had terminated a global licensing deal with BiosanaPharma for a biosimilar rival to Novartis’s Xolair (omalizumab), Alvotech has announced a fresh alliance wit

Alvotech has announced a five-product biosimilar commercialization deal with Advanz Pharma in Europe, capping a busy week that has also seen the biosimilars developer make a number of other key dis

Alvotech has delivered on recent indications that it would look to use in-licensing deals to supplement its in-house biosimilars pipeline, striking a licensing deal with BiosanaPharma that will see